Ribociclib in adiuvante nel tumore della mammella HR+/HER2-, lo studio NATALEE

Ribociclib in adiuvante nel tumore della mammella HR+/HER2-, lo studio NATALEE

[Oncoinfo – Istantanee di Oncologia: seguici su http://oncoinfo.it] È Valentina Guarneri (Direttore UOC Oncologia 2 – Istituto Oncologico Veneto e Professore Ordinario, Università di Padova) ad approfondire e commentare per noi i risultati del trial NATALEE su ribociclib in adiuvante, tra i più attesi ad ASCO 2023: il carcinoma mammario HR+, HER2- è infatti il sottotipo più comune della malattia e costituisce quasi il 70% di tutti i casi di tumore della mammella negli Stati Uniti e nel mondo.

ภาพตัวอย่างวิดีโอ
Ribociclib in adiuvante nel tumore della mammella HR+/HER2-, lo studio NATALEE
ภาพตัวอย่างวิดีโอ
Ribociclib nel trattamento adiuvante del tumore della mammella con recettori ormonali positivi
ภาพตัวอย่างวิดีโอ
HR+/HER2- breast cancer, with adjuvant CDK4/6 inhibitor risk of recurrence reduced by 28%
ภาพตัวอย่างวิดีโอ
Tumore mammella in stadio iniziale: ribociclib in adiuvante riduce di un quarto rischio di recidiva
ภาพตัวอย่างวิดีโอ
Tumore al seno HR+/HER2- avanzato, ribociclib aggiunto a letrozolo in prima linea allunga la vita
ภาพตัวอย่างวิดีโอ
Tumore al seno HR+HER2-, con inibitore di CDK4/6 adiuvante rischio di recidiva ridotto fino al 33%
ภาพตัวอย่างวิดีโอ
Update a 5 anni del trial NATALEE su ribociclib, una conversazione ad AIOM 2025
ภาพตัวอย่างวิดีโอ
ASCO 2023 highlights in breast cancer: NATALEE, monarchE, and PENELOPE-B
ภาพตัวอย่างวิดีโอ
Carcinoma mammario avanzato HR+/HER2-: ribociclib e terapia endocrina evitano la polichemioterapia?
ภาพตัวอย่างวิดีโอ
What to look forward to in breast cancer at ASCO 2023
ภาพตัวอย่างวิดีโอ
Follow-up a 4 anni dello studio NATALEE, quali aggiornamenti?
ภาพตัวอย่างวิดีโอ
Trial NATALEE, quali update da San Antonio?
ภาพตัวอย่างวิดีโอ
Tumore al seno HR+/HER2- iniziale, con abemaciclib adiuvante rischio di recidiva ridotto del 32%
ภาพตัวอย่างวิดีโอ
Lo studio BioItaLEE | Saverio Cinieri
ภาพตัวอย่างวิดีโอ
Tumore al seno HR+/HER2-, un panorama di trattamento in evoluzione
ภาพตัวอย่างวิดีโอ
Ca al seno, ribociclib aumenta il tempo senza progressione di malattia
ภาพตัวอย่างวิดีโอ
Tumore del seno, arriva in Italia abemaciclib
ภาพตัวอย่างวิดีโอ
Biopsia liquida e carcinoma della mammella
ภาพตัวอย่างวิดีโอ
Ribociclib Extends Lifespan in Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer
ภาพตัวอย่างวิดีโอ
Cancro al seno HR+/HER2- iniziale, ok europeo a inibitore di CDK4/6 per i casi ad alto rischio